Emcure Pharmaceuticals gets SEBI approval to launch IPO worth ₹800 crore, check key details

Emcure Pharmaceuticals Limited has filed with SEBI to raise funds through an IPO, via a fresh issue of ₹800 crore and an offer-for-sale of up to 13,678,839 shares, according to DRHP data. After the IPO has received the SEBI nod, it will be listed on NSE and BSE. The face value of each share is ₹10. The retail quota would be 35%, QIB 15%, and HNI 15%.

Details of the IPO

Emcure reported a revenue of ₹6,031.716 crore in 2023 against ₹5,918.86 crore in 2022. However, the profit after tax (PAT) fell to ₹561.845 crore in 2023 compared to ₹702.556 crore in 2022. The company’s peer group includes:

• Dr. Reddy’s Laboratories Limited
• Cipla Limited
• Alkem Laboratories Limited
• Torrent Pharmaceuticals Limited
• Mankind Pharma Limited
• Abbott India Limited
• J. B. Chemicals & Pharmaceuticals Limited

About Emcure

Emcure Pharmaceuticals Limited is a leading pharmaceutical company in the country that develops, manufactures, and markets various products, such as oral medications, injectables, and biotherapeutics.

Because of its strong research and development capacities, the company has a presence in over 70 countries, with a major foothold in India, Canada, and Europe. It focuses on gynecology, cardiovascular health, vitamins, minerals, and nutrients, HIV treatments, blood disorders, and oncology/anti-cancer medications.

According to a CRISIL report, Emcure is a leader in the Indian Pharmaceutical Market (IPM), with a slew of iron combination products. It holds significant positions in the field of gynecology in categories like Progestin, Gonadotropin, and Menstrual disorders. It has also established itself as the largest company in gynaecology and HIV antivirals by Domestic Sales for MAT September 2023.

Emcure has over 350 brands, five R&D centres, and 13 manufacturing units across India, ensuring a global footprint. The company focuses on innovation to deliver affordable and high-quality healthcare solutions globally.

To know more about IPOs listing, schedule and upcoming IPOs, click here